Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

@article{Mariani2009TrastuzumabAA,
  title={Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer},
  author={Gabriella Lucia Mariani and Angelica Fasolo and Elena De Benedictis and Luca Gianni},
  journal={Nature Clinical Practice Oncology},
  year={2009},
  volume={6},
  pages={93-104}
}
Trastuzumab has an established role for the treatment of HER2-positive early-stage breast cancer because of the success of this agent in the adjuvant setting. Several key questions about the value of trastuzumab for the treatment of breast cancer, however, still need to be answered. Various differences in patient characteristics and treatment regimens were… CONTINUE READING